Better prognosis to provide better treatment options
Given that colorectal cancer generally bears a particularly poor prognosis, and that there are few therapeutic options for these patients, MoTriColor strive to develop and validate new therapeutic options targeted and tailored to the particularities of each tumor and each individual patient. The Consortium estimates that between 25-30% of colorectal cancer patients with advanced disease, who have not responded to currently available, standard therapies, will present at least one gene expression profile that will permit their inclusion in early phase MoTriColor clinical studies.
Pioneering work leading to a first companion diagnostic test
If MoTriColor is successful, there will be significant economic upside for the EU knowledge economy through the introduction of molecular diagnostic tests in the clinical management of CRC.
Analysing resistant responses
MoTriColor will be able to identify patients that develop secondary resistance to our treatments and test (in a preclinical setting) new drugs or combinations that may be effective for those patients. In a long-term scenario, the newly identified biomarkers may be included in the already existing tool and help looking for alternative combinations for patients susceptible of developing secondary resistance.